A sign of things to come

A sign of things to come

Back when Medtronic (NYSE: MDT) announced their exclusive deal with UnitedHealthCare, the insulin pump community was up in arms fearing that this deal would limit patient choice. The connection was that patients would be forced into a Medtronic insulin pump and not allowed to use the pump of their choice due to cost considerations. Then in what smacks of outward hypocrisy many of these people were falling all over themselves to praise Medtronic when the FDA approved the 670G . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.